Gilead Sciences, Inc.
GILD- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000882095
In the last 90 days, Gilead Sciences, Inc. insiders filed 0 open-market purchases and 11 sales; 2,293 institutions reported holding it in 13F filings for Q2 2026, worth $140.5B in total; no superinvestor holds it.
13F holders, Q4 2021
Institutional positions in Gilead Sciences, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 1,685
- +144 vs. Q3 2021
- Shares held
- 1.01B
- +7.52M (+0.7%) vs. Q3 2021
- Total value
- $73.4B
- +$3.29B (+4.7%) vs. Q3 2021
- New holders
- 247
- 637 more added
- Sold out
- 103
- 597 more reduced
27 institutions that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting GILD on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 2,293 | $140.5B |
| Q1 2026 | 2,330 | $151.6B |
| Q4 2025 | 2,224 | $137.2B |
| Q3 2025 | 2,033 | $117.3B |
| Q2 2025 | 2,024 | $119.2B |
| Q1 2025 | 2,018 | $119.1B |
| Q4 2024 | 1,887 | $98.2B |
| Q3 2024 | 1,722 | $87.7B |
| Q2 2024 | 1,683 | $71.3B |
| Q1 2024 | 1,723 | $76.2B |
| Q4 2023 | 1,781 | $84.9B |
| Q3 2023 | 1,688 | $78.1B |
| Q2 2023 | 1,705 | $80.5B |
| Q1 2023 | 1,741 | $86.1B |
| Q4 2022 | 1,771 | $88.5B |
| Q3 2022 | 1,604 | $62.2B |
| Q2 2022 | 1,606 | $61.7B |
| Q1 2022 | 1,602 | $59.2B |
| Q4 2021 | 1,685 | $73.4B |
| Q3 2021 | 1,568 | $70.1B |
| Q2 2021 | 1,550 | $68.5B |
| Q1 2021 | 1,572 | $63.4B |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Gilead Sciences, Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Marshall Wace North America L.P. | – | – | – | – | Not filed |
| Elevated Capital Advisors, LLC | – | – | – | – | Not filed |
| Towarzystwo Funduszy Inwestycyjnych Pzu SA | – | – | – | – | Not filed |
| Mid Atlantic Financial Management Inc | – | – | – | – | Not filed |
| Ameritas Investment Company, LLC | – | – | – | – | Not filed |
| NorthCoast Asset Management LLC | – | – | – | – | Not filed |
| Homrich & Berg | – | – | – | – | Not filed |
| New England Investment & Retirement Group, Inc. | – | – | – | – | Not filed |
| Berman Capital Advisors, LLC | – | – | – | – | Not filed |
| Sonora Investment Management, LLC | – | – | – | – | Not filed |
| Wealth Quarterback LLC | – | – | – | – | Not filed |
| First Mercantile Trust Co | – | – | – | – | Not filed |
| Filbrandt Wealth Management, LLC | – | – | – | – | Not filed |
| Psagot Investment House Ltd. | – | – | – | – | Not filed |
| Heritage Wealth Management, LLC | – | – | – | – | Not filed |